The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders

ChemMedChem - United Kingdom
doi 10.1002/cmdc.201900176
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Front Cover: The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders (ChemMedChem 13/2019)

ChemMedChem
Organic ChemistryMolecular MedicinePharmacologyBiochemistryToxicologyDrug DiscoveryPharmaceutics
2019English

Histamine H3 Receptor Inverse Agonist Alleviate Mechanical Allodynia Through the Activation of H1R and H2R in Periaqueductal Gray Matter.

Proceedings for Annual Meeting of The Japanese Pharmacological Society
2020English

Effect of Histamine H3 Receptor Agonist on the Chemotherapy-Induced Fatigue in Mice

Proceedings for Annual Meeting of The Japanese Pharmacological Society
2020English

Fishing for Histamine H3 Receptor Functions

Acta Physiologica
Physiology
2017English

The Histamine Autoreceptor Is a Short Isoform of the H3 Receptor

British Journal of Pharmacology
Pharmacology
2012English

Immethridine, Histamine H3-Receptor (H3R) Agonist, Alleviated Experimental Autoimmune Encephalomyelitis via Inhibiting the Function of Dendritic Cells

Oncotarget
Oncology
2017English

The Brain H3-Receptor as a Novel Therapeutic Target for Vigilance and Sleep–wake Disorders

Biochemical Pharmacology
BiochemistryPharmacology
2007English

Enhanced Histaminergic Neurotransmission and Sleep-Wake Alterations, a Study in Histamine H3-Receptor Knock-Out Mice

Neuropsychopharmacology
PsychiatryMental HealthPharmacology
2013English

Discovery of S-(2-Guanidylethyl)-Isothiourea (VUF 8430) as a Potent Nonimidazole Histamine H4 Receptor Agonist

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy